Medical News

RSS

ImmunoGen announces underwriter's exercise of over-allotment option

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that the underwriters of its previously announced public offering of common stock have exercised in full their option to purchase 1,350,000 shares of common stock at a public offering price of $8.00 per share.

10 May 2010

Hospital operator HCA plans to offer $4.6 billion IPO

HCA Inc., the nation's biggest hospital operator by number of facilities, filed plans last week for a $4.6 billion initial public offering as it "looks to return to the public markets," The Wall Street Journal reports.

10 May 2010

PositiveID reports $673,000 revenue for first-quarter 2010

PositiveID Corporation announced that it has reported financial results for the quarter ended March 31, 2010, its first full quarter of operations since its acquisition of Steel Vault Corporation in November 2009 and the resulting name change to PositiveID. The Company reported revenues of $673,000 for the first quarter of 2010, compared to revenues of $8,000 for the first quarter of 2009.

10 May 2010

Today's Opinions: The need for federal review of rate increases; Dems and GOP share blame for health costs; A phoney deal on Medicaid

This hodgepodge of controls over premiums needs to be backstopped by a national law that would allow the federal government to block unjustified rate increases where state officials lack the authority to do so. Attempts to include such powers in the newly enacted health care reform law failed (5/9).

10 May 2010

BIOTX introduces Estrofil menopause supplements in North America

BIOTX Limited – a manufacturer and developer of dietary supplements based on Traditional Chinese Medicine, today launched Estrofil in North America - an all-natural nutritional menopause supplement for the relief of menopausal symptoms. This new menopause natural remedy is not estrogen or hormone replacement therapy.

10 May 2010

Connectyx to expand market presence in U.S. EHR market

Connectyx Technologies Holdings Group, Inc. is pleased to announce that the Company is set to expand its market presence in the U.S. Electronic Health Record (EHR) Market. The EHR market is poised to grow at a rate of 13.5 percent over the next four years, and by 2015 it will top $4.85 billion, according to a new study by Kalorama Information.

10 May 2010

Takeda appoints BNY Mellon as depositary bank for sponsored ADR program

BNY Mellon, the global leader in asset management and securities servicing, has been appointed by Takeda Pharmaceutical Company Limited (Takeda) as the depositary bank for its sponsored American depositary receipt (ADR) program. Each Takeda ADR represents one-half of a common share and trades on the over-the-counter (OTC) market under the symbol TKPYY. Takeda's common shares trade on the Tokyo Stock Exchange as well as four other exchanges in Japan under the code "4502." Previously, Takeda traded as an unsponsored ADR program serviced by multiple depositaries.

10 May 2010

Multicomponent psychological intervention helps reduce alexithymia and cancer pain

An Italian study published in the current issue of Psychotherapy and Psychosomatics examines the relationship between cancer pain and inability to express feelings and the effects of treatment.

10 May 2010

CVS calls on FDA to suspend use of contaminated rotavirus vaccines

On Friday, the Food and Drug Administration (FDA) convened a panel of experts to review recent findings that rotavirus vaccines given to infants in the U.S., Rotateq, produced by Merck Pharmaceuticals and Rotarix produced by GlaxoSmithKline, are contaminated with DNA from pig viruses PCV1 and PCV2. On March 22nd the FDA Commissioner asked doctors to suspend use of the Rotarix vaccine due to the contamination. Upon additional testing, Rotateq was also found to be contaminated.

10 May 2010

Companies get help to insure early retirees

Reporting for Kaiser Health News and USA Today, KHN staff writer Christopher Weaver reports: "The White House unveiled details last week of a $5 billion program to provide financial relief to companies that offer health coverage to early retirees.

10 May 2010

CHRISTUS Health selects Wolters Kluwer Health's ProVation Order Sets electronic solution

Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that CHRISTUS Health has selected ProVation® Order Sets, powered by UpToDate® Decision Support, as its electronic order set solution. In addition to automating development and maintenance, ProVation Order Sets will provide clinicians at 24 CHRISTUS facilities with point-of-care access to order sets and other intuitive clinical decision support tools.

10 May 2010

Study results of CTT's Calmare Pain Therapy for CIPN to be presented

Competitive Technologies, Inc. announced today that Thomas J. Smith, M.D., Endowed Chair of Palliative Care Research and Medical Director of the Thomas Palliative Care Unit Virginia Commonwealth University's Massey Cancer Center, will present results of his study evaluating the treatment of patients suffering from pain associated with chemotherapy-induced peripheral neuropathy (CIPN) using CTT's Calmare® Pain Therapy Treatment.

10 May 2010

Generex Biotechnology enrolls over 400 subjects in global Phase III study of Generex Oral-lyn

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has achieved enrolled of over 400 subjects in its pivotal global Phase III study of its flagship product, Generex Oral-lyn™, a proprietary buccal insulin spray product designed to replace prandial injections of insulin.

10 May 2010

FDA grants EUA for IQuum's Liat Influenza A/2009 H1N1 Assay

IQuum, Inc. today announced it has been granted an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Liat™ Influenza A/2009 H1N1 Assay. The assay detects and differentiates 2009 H1N1 influenza viral RNA starting from collected nasopharyngeal swab samples in less than 30 minutes.

10 May 2010

Eisai enters Canadian pharmaceutical market

Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd. today announces the establishment of Eisai Limited in Canada, the world's ninth largest pharmaceutical market. As a wholly-owned subsidiary of Eisai Inc., Eisai Limited will be based in Mississauga, Ontario, one of the largest biopharmaceutical clusters and medical communities in North America.

10 May 2010

Companies await health IT windfall

The Washington Post: A Virginia firm, Vangent, is positioning "itself for a surge of federal spending on health information technology" by setting up a health IT strategy group. "Vangent is likely to face stiff competition for those dollars, but company officials say they expect the firm's reputation as a health-related services provider to serve it well as it bids on contracts." The firm is also involved in civil, defense and national security work, but health services are its largest business.

10 May 2010

Enzon reports income from continuing operations of $20.8M for first-quarter 2010

Enzon Pharmaceuticals, Inc. today announced its financial results for the first quarter of 2010. During the quarter, the Company completed the sale of its specialty pharmaceutical business. This transaction has now transformed the Company, both financially and operationally, into a biopharmaceutical company dedicated to the discovery and development of oncology medicines.

10 May 2010

ACM receives Health Utilization Management Accreditation from URAC

Akeso Care Management®, Inc. (ACM®) announced today that it has been awarded Health Utilization Management Accreditation by URAC, a leading health care accrediting organization that establishes quality standards for the health care industry. ACM provides medical management services to domestic and international insurance carriers, self-insured employers and third party administrators.

10 May 2010

QRxPharma reports successful outcome of Phase 1 trial for MoxDuo CR for chronic pain

QRxPharma announced today the successful outcome of a Phase 1 trial for MoxDuo CR, a controlled-release (CR) Dual-Opioid(TM) designed to provide 12 hours of pain relief in patients suffering from moderate to severe chronic pain (including cancer, lower back, osteoarthritis and neuropathic). The purpose of the trial was to determine which of the various experimental formulations provided the optimum duration of drug levels in the blood.

10 May 2010

Nearly half of IT security professionals believe personal healthcare information is less secure than before

Forty-seven percent of IT security professionals believe their personal healthcare information is less secure than it was 12 months ago according to a recent survey by nCircle, the leading provider of automated IT security and compliance auditing solutions.

10 May 2010

Medical News

ImmunoGen announces underwriter's exercise of over-allotment option

Hospital operator HCA plans to offer $4.6 billion IPO

PositiveID reports $673,000 revenue for first-quarter 2010

Today's Opinions: The need for federal review of rate increases; Dems and GOP share blame for health costs; A phoney deal on Medicaid

BIOTX introduces Estrofil menopause supplements in North America

Connectyx to expand market presence in U.S. EHR market

Takeda appoints BNY Mellon as depositary bank for sponsored ADR program

Multicomponent psychological intervention helps reduce alexithymia and cancer pain

CVS calls on FDA to suspend use of contaminated rotavirus vaccines

Companies get help to insure early retirees

CHRISTUS Health selects Wolters Kluwer Health's ProVation Order Sets electronic solution

Study results of CTT's Calmare Pain Therapy for CIPN to be presented

Generex Biotechnology enrolls over 400 subjects in global Phase III study of Generex Oral-lyn

FDA grants EUA for IQuum's Liat Influenza A/2009 H1N1 Assay

Eisai enters Canadian pharmaceutical market

Companies await health IT windfall

Enzon reports income from continuing operations of $20.8M for first-quarter 2010

ACM receives Health Utilization Management Accreditation from URAC

QRxPharma reports successful outcome of Phase 1 trial for MoxDuo CR for chronic pain

Nearly half of IT security professionals believe personal healthcare information is less secure than before

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Latest News